At a glance
ABLS charges 0.39% a year. It has $465K in assets; it paid 12.9% of its price in distributions over the past 12 months, quarterly. Over the past year it returned +7.7% with distributions reinvested (S&P 500: +11.5%). Its ten largest positions make up 50.1% of the fund, out of 46 in all.
The short version
Abacus FCF Small Cap Leaders ETF (ABLS) tracks the Abacus FCF Small Cap Leaders Index: up to 50 U.S. small companies scored on free cash flow return on invested capital, or how much spare cash a business generates from the money invested in it. It is concentrated (Argan Inc. alone was 11.8% of assets on July 31, 2026) and tiny, with $464,508 in net assets. It charges 0.39% after a 0.20% fee waiver.
Price history
The interactive chart needs JavaScript.
ABLS +7.7% over the year to Oct 27, 2026, total return with distributions reinvested.
How it has behaved
| YTD | 1 yr | 3 yr | 5 yr | 10 yr | Since start | |
|---|---|---|---|---|---|---|
| ABLS official prospectus, to Dec 31, 2024 | — | +9.29% | — | — | — | +6.95% |
| ABLS price data to Oct 27, 2026 | +11.2% | +7.7% | — | — | — | +0.9% |
- Over the year to Oct 27, 2026, ABLS returned +7.7%.
- The deepest fall in its price history was 19.3% (Feb 19, 2025 to Mar 26, 2026), recovered by Jun 18, 2026.
Show as a table
| Year | Price data | Prospectus (official) |
|---|---|---|
| 2026 (to date) | +11.2% | — |
| 2024 | — | +9.29% |
| 2023 | — | +26.78% |
| 2022 | — | -19.78% |
| 2008 financial crisis stocks fell Oct 9, 2007 – Mar 9, 2009 | Before this security existed |
|---|---|
| 2020 COVID crash stocks fell Feb 19, 2020 – Mar 23, 2020 | Before this security existed |
| 2022 bear market stocks fell Jan 3, 2022 – Oct 12, 2022 | Before this security existed |
Dividends and income
Show as a table
| Year | Per share | Change |
|---|---|---|
| 2026 (to date) | $0.1420 |
What's inside
As of Jul 31, 2026, the fund held 46 securities; the ten largest made up 50.14% of assets. It also reported 3.51% in a money-market fund, most likely cash collateral from lending out shares rather than uninvested money.
| Holding | Weight | |
|---|---|---|
| Argan Inc | 11.79% | |
| Enova International Inc | 6.46% | |
| Oscar Health Inc | 5.83% | |
| Artisan Partners Asset Managem | 4.38% | |
| Collegium Pharmaceutical Inc | 4.27% | |
| Healthcare Services Group Inc | 3.73% | |
| Harmony Biosciences Holdings I | 3.58% | |
| Qualys Inc | 3.40% | |
| Kontoor Brands Inc | 3.39% | |
| Progyny Inc | 3.32% | |
| Pediatrix Medical Group Inc | 2.83% | |
| PJT Partners Inc | 2.72% | |
| Cohen & Steers Inc | 2.69% | |
| World Acceptance Corp | 2.48% | |
| LiveRamp Holdings Inc | 2.42% |
By country
United States 97.45%By asset type
Stocks 97.45%What changed recently
- Over the three months to Jul 31, 2026, investors withdrew a net $899K (creations minus redemptions, per the N-PORT report).
- Monthly total returns reported for that quarter: +2.97%, +12.92%, -3.52%.
How it works
ABLS tracks the Abacus FCF Small Cap Leaders Index. Its provider, Abacus FCF Indexes LLC, is affiliated with the fund's adviser, a potential conflict of interest the prospectus discloses. Eligible stocks must be US-listed, trade enough shares, come from companies that reported free cash flow, net income and revenue within the past year, and be small-cap, defined as $7.4 billion or less in market value as of September 30, 2025.
The adviser's Abacus FCF Leaders Model scores each stock on free cash flow return on invested capital: cash left after running and reinvesting in the business, relative to the capital invested. It weighs factors such as capital spending, accruals (profits booked before cash arrives) and cash-flow margins. Scores are adjusted for risk using each stock's price swings over the prior 12 months, then combined with each company's market value. Stocks are added until they cover over 90% of total weight or hit 50 names, then reweighted.
The index and fund are rebalanced each quarter, adding and dropping stocks, with a 25% turnover cap; the prospectus reports 83% portfolio turnover. The fund may use exchange-traded futures but held no derivatives as of July 31, 2026. It is non-diversified, so single holdings can be large: Argan Inc was 11.8% that day. As of September 30, 2025, the index was concentrated in information technology.
What it really costs
- ABLS charges 0.39% a year.
- Of that, 0.59% is the management fee; the rest covers other fund expenses.
- The fee includes a 0.2% waiver from the adviser, which may end.
- Using the prospectus's standard example, $10,000 invested would cost about $40 in the first year and $719 over 10 years (assuming a 5% annual return).
| Cost of $10,000 (SEC example) | 1 yr | 3 yrs | 5 yrs | 10 yrs |
|---|---|---|---|---|
| ABLS | $40 | $169 | $309 | $719 |
In a retirement portfolio
As of July 31, 2026, it held a concentrated, non-diversified basket of 46 small U.S. companies, and its trading record is short, so it fits a small slice of a portfolio rather than its core.
ABLS could add a tilt toward small U.S. companies with strong free cash flow. Its trading record starts in February 2025, after the 2008, 2020 and 2022 downturns, though the prospectus reports a 19.78% loss for 2022, its worst year shown. Since trading began, its deepest drop was 19.3%, from February 19, 2025, to March 26, 2026; it recovered by June 18, 2026, about 2.8 months later. Cashing out near that low would have locked in losses.
Distributions are paid quarterly. The trailing yield was 12.9% as of October 27, 2026, unusually high for a stock fund, so it can reflect one-off payouts that may not repeat. The prospectus warns the fund is less tax efficient than other ETFs. The expense ratio is 0.39% after a fee waiver. Past results don't predict the future, and a plan should weigh the whole portfolio, not one fund.
Who it may suit — and who should look elsewhere
May suit
- Investors wanting a rules-based tilt toward U.S. small caps scored on free cash flow return on invested capital, held alongside broader core funds.
- Investors who can ride out swings like the 19.3% fall from February 2025 to March 2026 without needing to cash out.
- Investors using a tax-advantaged account, where the prospectus warning about lower tax efficiency and the 83% portfolio turnover matter less.
Look elsewhere if
- Those wanting broad diversification: the fund is non-diversified; Argan Inc. was 11.8% and the top 10 were 50.14% of assets on July 31, 2026.
- Anyone uneasy with a tiny fund: net assets were $464,508 on July 31, 2026, after $898,720 of net outflows over three months.
- Retirees counting on steady income: the 12.9% trailing yield as of October 27, 2026, is unusually high for stocks and may not repeat.
Close alternatives
Matched by holdings overlap from the latest N-PORT reports.
No close alternatives found.
Questions investors ask
What does ABLS invest in?
ABLS holds U.S. small-company stocks picked by the Abacus FCF Small Cap Leaders Index. The index scores small caps on free cash flow return on invested capital and adjusts for each stock's volatility over the preceding 12 months. It holds up to 50 names and rebalances quarterly. The index is run by Abacus FCF Indexes LLC, an affiliate of the fund's adviser, which the prospectus flags as a potential conflict of interest. As of July 31, 2026, Argan Inc. (11.8%), Enova International (6.5%) and Oscar Health (5.8%) were the largest holdings.
Does ABLS pay dividends?
Yes. ABLS pays distributions quarterly. Over the 12 months to October 27, 2026, it paid $2.855 per share, a trailing yield of 12.9%. That is far above what small-company stocks usually yield, so it can reflect one-off payouts, such as capital gains distributions, that may not repeat. The prospectus also warns the fund is less tax efficient than other ETFs because a seed investor contributed its starting portfolio at a low cost basis (the original price used for tax purposes).
What is the ABLS expense ratio?
ABLS's expense ratio, the yearly fee taken from fund assets, is 0.39%, according to its prospectus filed November 26, 2025. That is a 0.59% management fee minus a 0.20% fee waiver. In the SEC's standard example ($10,000 invested, a 5% yearly return, shares cashed out at the end of each period), total costs are $40 after one year, $169 after three, $309 after five and $719 after ten. The longer-period figures run higher than a steady 0.39% would produce, a sign the waiver may not last.
Is ABLS good for retirement?
ABLS fits more naturally as a small add-on to core funds than as a core retirement holding. It is non-diversified, meaning it can put more money in a single company, and its top 10 holdings made up 50.14% of assets on July 31, 2026. Its own trading record starts in February 2025; its price fell 19.3% from February 19, 2025, to March 26, 2026, before recovering by June 18, 2026. With $464,508 in net assets, it is also very small, which raises the risk of closure.
How has ABLS performed?
ABLS gained 7.7% in the year to October 27, 2026, and 11.2% in 2026 through that date, based on market price. Its prospectus reports a 19.78% loss in 2022, a 26.78% gain in 2023 and a 9.29% gain in 2024, all earlier than the ETF's own trading record, which starts in February 2025. In the prospectus figures, the strongest quarter gained 13.43% (ended September 30, 2024) and the weakest lost 15.41% (ended June 30, 2022). Past returns don't predict future results.